Tech Company Financing Transactions

ADARx Pharmaceuticals Funding Round

ADARx Pharmaceuticals secured a $200 million Series C funding round on 8/9/2023. Investors included Bain Capital Life Sciences, Ascenta Capital and BlackRock.

Transaction Overview

Company Name
ADARx Pharmaceuticals
Announced On
8/9/2023
Transaction Type
Venture Equity
Amount
$200,000,000
Round
Series C
Investors

Bain Capital Life Sciences (Lead Investor)

Ascenta Capital (Lorence Kim)

BlackRock

Commodore Capital

Cormorant Asset Management

HBM Healthcare Investments

private investors (Marshall Wace)

Invus

Lilly Asia Ventures

OrbiMed

Redmile Group

SR One Capital Management

T. Rowe Price

TCG Crossover

Venrock Healthcare Capital Partners

Vivo Capital

Proceeds Purpose
The proceeds from the Series C financing will be used to further advance ADARx clinical programs including ADX-324 and ADX-038. ADX-324 represents an innovative approach for the treatment of hereditary angioedema, a rare genetic disease that causes painful, rapid, and potentially life-threatening swelling attacks, while ADX-038 is being developed for the treatment of multiple complement mediated diseases. The funding will also support advancement of a pipeline of innovative mRNA silencing or editing candidates for the treatment of a broad range of diseases.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5871 Oberlin Dr. 200
San Diego, CA 92121
USA
Phone
(877) 232-7974
Website
www.adarx.com
Email Address
[email protected]
Overview
ADAR is an acronym for Adenosine Deaminase Acting on RNA. As such, our name may make you think of RNA editing, but that's only part of the story. The word adar means wide or great which aptly describes the opportunities for our RNA targeting platform.
Profile
ADARx Pharmaceuticals LinkedIn Company Profile
Social Media
ADARx Pharmaceuticals Company Twitter Account
Company News
ADARx Pharmaceuticals News
Facebook
ADARx Pharmaceuticals on Facebook
YouTube
ADARx Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Zhen Li
  Zhen Li LinkedIn Profile  Zhen Li Twitter Account  Zhen Li News  Zhen Li on Facebook
Vice President
Melissa Fisher
  Melissa Fisher LinkedIn Profile  Melissa Fisher Twitter Account  Melissa Fisher News  Melissa Fisher on Facebook
Vice President
Timothy Young
  Timothy Young LinkedIn Profile  Timothy Young Twitter Account  Timothy Young News  Timothy Young on Facebook
VP - R & D
Rui Zhu
  Rui Zhu LinkedIn Profile  Rui Zhu Twitter Account  Rui Zhu News  Rui Zhu on Facebook

 

 

Browse more venture capital transactions:

Prev: 8/9/2023: Kraftblock venture capital transaction
Next: 8/9/2023: Georgiamune venture capital transaction

 

Share this article

 

About Database of VC Transactions

Our team works diligently to document every notable VC transaction. All VC database entries reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.